Photo from wikipedia
Comprehensive genomic profiling (CGP) has been approved in Japan since June 2019, enabling mutation‐specific therapy. Although tissue sampling via endoscopic ultrasound‐guided tissue acquisition (EUS‐TA) is standard in pancreatic cancer, reports… Click to show full abstract
Comprehensive genomic profiling (CGP) has been approved in Japan since June 2019, enabling mutation‐specific therapy. Although tissue sampling via endoscopic ultrasound‐guided tissue acquisition (EUS‐TA) is standard in pancreatic cancer, reports on obtaining appropriate samples for CGP, especially for the OncoGuide NCC Oncopanel System (NOP) and FoundationOne CDx (FOne), are lacking. Therefore, we investigated the success rate and factors related to appropriate EUS‐TA sampling for CGP analysis suitability in unresectable pancreatic ductal adenocarcinoma (UR‐PDAC).
Journal Title: Digestive Endoscopy
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!